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Results and Discussion
The adoptive transfer of clinical EAE is readily achieved with spleen cells obtained from BP-sensitized donors if these cells are stimulated in vitro with specific antigen before transfer . Table I shows the development of adoptively transferred clinical EAE in syngeneic and semisyngeneic, but not allogeneic recipients of BP-stimulated spleen cells obtained from BP-CFA-immunized Lewis (LEW) and (ACI X LEW)F1 rats. These results are consistent with other reports of MHC restriction in the transfer of EAE in the rat (6, 7) . In addition to exhibiting a requirement for MHC compatibility, presumably reflecting the need for in vivo antigen presentation requirements, transferred cells must escape host rejection mechanisms during the inductive phase of the disease. For example, clinical EAE develops in experiments where LEW cells are transferred to F344 rats or (LEW X BN)F, cells are transferred to LEW rats only if the recipient is irradiated before transfer . While these donor-recipient combinations have shared MHC antigens, recipient recognition of foreign non-MHC antigens on the transferred cells apparently inhibits donor cell function in the nonirradiated recipient. Irradiation of recipients before transfer, however, does not allow MHC-incompatible cells to transfer EAE, indicating a requirement for proper antigen presentation within the recipient.
The restriction patterns seen in Table I sented in Table II demonstrate The chimeras used in this study were designed to test the potential influence of non-bone marrow-derived cells on the development of adoptively transferred EAE. Endothelial cells isolated from the cerebral vasculature express la when isolated from SJL mice exhibiting clinical EAE, but Ia+ endothelial cells are not found in similar preparations from normal syngeneic mice (1) . In guinea pigs immunized with BP, endothelial cells become Ia+ just before disease onset (9) . However, in (Strain 2 X Strain 13)1`1 hybrids, only the high-responder strain 13 haplotype is expressed on endothelial cells of BP-sensitized guinea pigs (10) . Large numbers of Ia' cells are also found in multiple sclerosis brain lesions, especially in the peripheral areas of the expanding plaque (11). These observations have led some investigators to suggest that endothelial cells may have a relevant role in antigen presentation in vivo (9, 12) , making them an active and central participant in the expression of antigen-specific delayed-type hypersensitivity responses (13) in general and in the development of the autoimmune response to antigens of the central and peripheral nervous tissue .
Our results question the need for MHC-restricted antigen presentation by endothelial cells in vivo . cells. However, chimeric recipients of the (LEW x BN)F,-+BN construct would possess non-bone marrow-derived cells allogeneic to the transferred LEW spleen cells. Since Table II shows that these chimeric recipients develop and recover from clinical disease with the same kinetics as syngeneic recipients, any MHCrestricted antigen-presenting function by these non-bone marrow-derived cells is not required for the development of adoptively transferred EAE.
We have previously shown (7) that rats that have recovered from adoptively transferred EAE can serve as a source of transfer-active cells and that this transfer-active population is derived from the original donor cell inoculum . It is evident from the data presented in Table II that recovery from adoptively transferred clinical disease in the BN chimeras is temporally consistent with recovery after syngeneic transfer of clinical disease. Furthermore, spleen cells obtained from chimeric recipients of transfer-active LEW cells can serve as a population of transfer-active cells (Table III) . Notably, serial transfer of EAE by this cell population is still dependent on in vitro activation by spleen cells. The recipient combinations exhibiting successful serial transfer of clinical disease also suggest that BP-specific LEW cells survive in the chimeric environment and can subsequently transfer clinical disease to LEW recipients . In contrast, serial transfer to BN or ACI recipients was not successful. These latter results also support our previous observations (7) that the development of adoptively transferred EAE does not result in the recruitment of BP-reactive cells derived from the recipient's lymphoid compartment.
If the endothelium does not play an active, antigen-presenting role in the development of EAE, how then does the inflammatory lesion develop? The ability to transfer EAE to a recipient in which the endothelium is allogeneic to the transferred cells may be explained by an interaction of T cells, T cell products, and mast cells (14) (15) (16) (17) . In support of this model we (18) and others (19) (20) (21) (22) have reported that the clinical signs of EAE can be prevented in animals that have received compounds that alter mast cell release of histamine and serotonin.
In addition to lending indirect support of the Askenase-Loveren model of DTH (17) (Table II) indicates that the presence of semisyngeneic F, bone marrow-derived accessory cells are sufficient for disease induction, even though the transferred lymphocytes are allogeneic to the CNS . In these donor-recipient combinations the only possible MHC compatibility is with the transferred lymphocytes and the established bone marrow . Non-bone marrow-derived -CNS tissue would not display MHC compatibility with the transferred lymphocytes. Consequently, MHC-restricted cytotoxic cells would not be expected to function in the development of clinical disease . Our observation that the endothelium need not be MHC compatible with BPspecific lymphocytes to have these cells function in vivo may be relevant to general considerations of the role of Ia+, non-bone marrow-derived cells and the antigen-presenting requirement for delayed-type hypersensitivity responses . It is probable within the syngeneic system that all Ia' cells, independent of origin, are involved in antigen presentation at some point in the immune response. However, the results of our studies would argue that any antigen-presenting function of endothelial cells in vivo is secondary to that of bone marrow-derived cells and that the development of EAE is not influenced by the lack of antigen presentation, or of compatible Ia+ expression, by cells of the endothelial barrier .
Summary
The adoptive transfer of clinical and histopathologic signs of experimental allergic encephalomyelitis (EAE) requires MHC compatibility between cell donor and cell recipient . The results of adoptive transfer studies using F, to parent bone marrow chimeras as recipients of parental-derived BP-sensitive spleen cells indicate that this restriction is not expressed at the level of the endothelial cell but is confined to the cells ofbone marrow derivation. Furthermore, these results indicate that the development of EAE is not dependent on the activity of MHCrestricted cytotoxic cells.
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